CN102416036B - Traditional Chinese medicinal compositions for preventing and treating ventricular reconstruction due to coronary heart disease and use thereof - Google Patents
Traditional Chinese medicinal compositions for preventing and treating ventricular reconstruction due to coronary heart disease and use thereof Download PDFInfo
- Publication number
- CN102416036B CN102416036B CN201110407138.XA CN201110407138A CN102416036B CN 102416036 B CN102416036 B CN 102416036B CN 201110407138 A CN201110407138 A CN 201110407138A CN 102416036 B CN102416036 B CN 102416036B
- Authority
- CN
- China
- Prior art keywords
- parts
- heart disease
- water
- coronary heart
- decoct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to use of Chinese medicinal compositions in preparation of medicines for preventing and treating ventricular reconstruction due to coronary heart disease. One Chinese medicinal composition is prepared from the following raw material medicines in part by weight: 20 to 40 parts of astragalus, 2 to 4 parts of scorpio and 4 to 8 parts of centipede. The Chinese medicinal composition has obvious effect on prevention and treatment of ventricular reconstruction due to coronary heart disease. The invention also relates to another Chinese medicinal composition which also comprises 9 to 15 parts of peach kernel, 10 to 20 parts of bitter orange and 40 to 70 parts of root of red-rooted salvia besides 20 to 40 parts of astragalus, 2 to 4 parts of scorpio and 4 to 8 parts of centipede. The components have qi-regulating, blood-activating and stasis-eliminating effects, so the treatment effect is improved; meanwhile, the Chinese medicinal composition medicines have wide application range and fewer side and toxic effects, fewer raw material components are needed, the raw materials are rich, the price is low, the preparation process is simple, and the Chinese medicinal compositions are suitable to be widely used.
Description
Technical field
The present invention relates to a kind of purposes of Chinese medicine composition, specifically, is that a kind of Chinese medicine composition is prevented and treated the application in coronary heart disease remodeling ventricle medicine in preparation.
Background technology
Coronary heart disease is a kind of modal heart disease, refers to the myocardial dysfunction and/or the organic disease that because of coronary stricture, blood supply insufficiency, cause, therefore claim again ischemic heart desease.Symptoms is that a kind of pain of squeezing property occurs in thoracic cavity central authorities, and can delay to neck, chin, arm, back and stomach.Other of outbreak may symptoms have dizzy, tachypnea, perspire, shiver, feel sick and faint, and severe patient may be because heart failure and death.
Coronary heart disease can cause remodeling ventricle, as acute myocardial infarction and severe coronary artery disease triple vessel disease, all has the pathological state of remodeling ventricle and the clinical symptoms of bringing in various degree.So-called remodeling ventricle refers to a series of variations such as size, shape, chamber wall thickness and the organizational structure that ventricle produces because myocardial damage or load increase, and is the pathologic-physiological reaction process of the compensatory and secondary of pathological changes reparation and ventricle entirety.
The starting stage forming from coronary heart disease remodeling ventricle talks about, after initial stage myocardial damage, compensatory mechanism activates, the load of ventricle increases the weight of, now, the function of heart is still adjustable to physiological range or just has slight reduction, and it is not obvious that patient feels symptom, or only have the symptoms such as work tachypnea, paroxysmal nocturnal dyspnea, easy fatigue, cough, belong to the early stage of heart failure.Along with the continuous hypertrophy of ventricle, cardiac function can constantly worsen, left ventricle cannot be discharged enough arterial bloods and meet the needs of health again, the symptom of heart failure is just more and more obvious, the symptoms such as dyspnea appears in patient, it is sleeping to put down, palpitation and short breath, tired weak, oliguria edema, more obvious after work, even some patient cannot carry out physical exertion.After significant change occurs for the planform of ventricle and size, cardiac contractility ability declines, especially by ellipse gradually become spherical after, cause mitral incompetence, ventricle blood discharge amount more cannot meet the needs of body.This is because mitral position, between left atrium and left ventricle, enters left atrium containing oxygen arterial blood through pulmonary vein, then by Bicuspid valve, enters left ventricle, when left ventricular contraction, MC, arterial blood is just entered aorta by " pump ", and then is transported to whole body.After the spherical variation of ventricle, mitral incompetence, arterial blood is along with some anti-left atrium that flows back to is understood in the contraction of left ventricle, thereby entering aortal blood volume will reduce, cannot meet body requirement, heart failure reaches late period, and remodeling ventricle is obvious and cardiac dilatation is more acute, and above-mentioned symptoms of heart failure is more obvious.Now, conditions of patients danger, painful abnormal, mortality rate is high.Therefore active intervention to coronary heart disease remodeling ventricle, prevent that the generation of heart failure, cardiac function protecting are most important.
At present aspect the preventing and treating of coronary heart disease remodeling ventricle, medication effect is very limited, and not all coronary heart disease remodeling ventricle is all applicable to operative treatment, as severe coronary artery disease triple vessel disease remodeling ventricle had both been not suitable for coronary intervention, is not suitable for again coronary bypass surgery and carries out myocardial revascularization.And utilize Chinese medicine to improve coronary heart disease remodeling ventricle, it may be an effective approach.
Chinese patent literature CN 200710038185.5,2010 days for announcing December 1 day, disclose a kind of Radix Scrophulariae and prevented and treated the application in myocardial hypertrophy, hypertrophic neuropathy and chronic heart failure medicine in preparation, this invention has confirmed that Radix Scrophulariae water or ethanol extract have the effect of myocardial hypertrophy due to obvious anti-many reasons, remodeling ventricle, chronic heart failure, its mechanism of action is obviously relevant to the excessive activation that suppresses the neuroendocrine system such as Re-A-A, the while also to reduce blood pressure, decreased heart rate, the hemodynamic effect of improvement be relevant, Chinese patent literature CN 200810055183.1, on December 2nd, open day, disclose a kind of Chinese medicine composition and suppressed the application in apoptosis of cardiac muscle medicine in preparation, described Chinese medicine composition is made by the crude drug of following weight portion: Radix Astragali 150-450 part, Radix Aconiti Lateralis Preparata 40-120 part, Radix Ginseng or Radix Codonopsis 75-225 part, Radix Salviae Miltiorrhizae 75-225 part, Semen Lepidii (Semen Descurainiae) 50-150 part, Cortex Periplocae or CORTEX ACANTHOPANACIS 60-180 part, Rhizoma Alismatis 75-225 part, Rhizoma Polygonati Odorati 25-75 part, Ramulus Cinnamomi 30-90 part, Flos Carthami 30-90 part, Pericarpium Citri Reticulatae 25-75 part, this Chinese medicine composition can suppress Patients with Chronic Heart Failure apoptosis of cardiac muscle, improve remodeling ventricle.The shortcomings such as but curative effect that these medicines still exist treatment remodeling ventricle is remarkable, flavour of a drug number is too much, preparation technology is loaded down with trivial details, therefore, need that one can effectively prevent and treat that coronary heart disease remodeling ventricle, flavour of a drug number are less badly, crude drug wide material sources, the simple medicine of preparation method, but about this class medicine, have not been reported at present.
Summary of the invention
The object of the invention is, for deficiency of the prior art, provides a kind of purposes of Chinese medicine composition.
One object more of the present invention is that a kind of Chinese medicine composition of preventing and treating coronary heart disease remodeling ventricle is provided.
For achieving the above object, the technical scheme that the present invention takes is:
Described Chinese medicine composition is to be made by the crude drug of following weight portion: Radix Astragali 20-40 part, Scorpio 2-4 part, Scolopendra 4-8 part.
Described Chinese medicine composition is mainly to be made by the crude drug of following weight portion: 30 parts of the Radixs Astragali, 3 parts of Scorpios, 6 parts of Scolopendras.
Described coronary heart disease remodeling ventricle is left ventricular remodeling due to after acute myocardial infarction and the remodeling ventricle due to coronary heart disease triple vessel disease.
For realizing above-mentioned another object, the technical scheme that the present invention takes is:
A Chinese medicine composition of preventing and treating coronary heart disease remodeling ventricle as above, described Chinese medicine composition also comprises the crude drug of following weight portion: Semen Persicae 9-15 part.
The weight portion of described Semen Persicae is 12 parts.
Described Chinese medicine composition also comprises the crude drug of following weight portion: Fructus Aurantii 10-20 part, Radix Salviae Miltiorrhizae 40-70 part.
The weight portion of described Fructus Aurantii is 15 parts, and the weight portion of described Radix Salviae Miltiorrhizae is 50 parts.
The medicament of described Chinese medicine composition is capsule, granule, tablet, oral liquid, mixture or syrup.
The invention has the advantages that:
1, the invention provides Chinese medicine composition Radix Astragali 20-40 part, Scorpio 2-4 part, Scolopendra 4-8 part and prevent and treat the application in coronary heart disease remodeling ventricle medicine in preparation, this medicine is started with from disease mechanism, the Radix Astragali is monarch's replenishing qi and promoting blood flow, ministerial drug Scorpio, Scolopendra activating blood circulation to dissipate blood stasis dredging collateral, prevent and treat coronary heart disease remodeling ventricle curative effect obviously, have no side effect, and flavour of a drug are few, raw material is easy to get.
2, the present invention also provides a kind of Chinese medicine composition of preventing and treating coronary heart disease remodeling ventricle, it is on the basis of said medicine, assistant is with Semen Persicae blood circulation promoting and blood stasis dispelling, Fructus Aurantii vital energy regualting and blood circulation-promoting, Radix Salviae Miltiorrhizae blood circulation promoting and blood stasis dispelling, tranquilizing by nourishing the heart, all medicines share plays benefiting QI for activating blood circulation altogether, regulating qi and dredging collateral, the effect of tranquilizing by nourishing the heart, in pharmacology, these Chinese medicines have coronary artery dilating, antiplatelet aggregation, antithrombotic forms, reduce blood viscosity, improve microcirculatory effect, the effect of preventing and treating coronary heart disease remodeling ventricle is more remarkable, and this Chinese medicine composition medicine wide ranges of suiting the medicine to the illness, no side effects, raw material components is few, abundant raw materials, low price, preparation technology is simple, be applicable to promoting the use of.
The specific embodiment
Below the specific embodiment provided by the invention is elaborated.
embodiment 1
prevent and treat the oral liquid preparation () of coronary heart disease remodeling ventricle medicine one
Get 20 parts of Chinese medicine astragalus, 4 parts of Scorpios, 4 parts of Scolopendras, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 2
prevent and treat the oral liquid preparation (two) of coronary heart disease remodeling ventricle medicine one
Get 40 parts of Chinese medicine astragalus, 2 parts of Scorpios, 8 parts of Scolopendras, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 3
prevent and treat the oral liquid preparation (three) of coronary heart disease remodeling ventricle medicine one
Get 20 parts of Chinese medicine astragalus, 4 parts of Scorpios, 8 parts of Scolopendras, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 4
prevent and treat the oral liquid preparation (four) of coronary heart disease remodeling ventricle medicine one
Get 40 parts of Chinese medicine astragalus, 2 parts of Scorpios, 4 parts of Scolopendras, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 5
prevent and treat the oral liquid preparation (five) of coronary heart disease remodeling ventricle medicine one
Get 20 parts of Chinese medicine astragalus, 4 parts of Scorpios, 7 parts of Scolopendras, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 6
prevent and treat the oral liquid preparation (six) of coronary heart disease remodeling ventricle medicine one
Get 40 parts of Chinese medicine astragalus, 2 parts of Scorpios, 6 parts of Scolopendras, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 7
prevent and treat the oral liquid preparation (seven) of coronary heart disease remodeling ventricle medicine one
Get 30 parts of Chinese medicine astragalus, 3 parts of Scorpios, 6 parts of Scolopendras, 12 parts, Semen Persicae, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 8
prevent and treat the oral liquid preparation (eight) of coronary heart disease remodeling ventricle medicine one
Get 25 parts of Chinese medicine astragalus, 3 parts of Scorpios, 7 parts of Scolopendras, 11 parts, Semen Persicae, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 9
prevent and treat the oral liquid preparation (nine) of coronary heart disease remodeling ventricle medicine one
Get 35 parts of Chinese medicine astragalus, 4 parts of Scorpios, 5 parts of Scolopendras, 13 parts, Semen Persicae, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 10
prevent and treat the oral liquid preparation (ten) of coronary heart disease remodeling ventricle medicine one
Get 25 parts of Chinese medicine astragalus, 2 parts of Scorpios, 7 parts of Scolopendras, 12 parts, Semen Persicae, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 11
prevent and treat the oral liquid preparation (11) of coronary heart disease remodeling ventricle medicine one
Get 40 parts of Chinese medicine astragalus, 2 parts of Scorpios, 6 parts of Scolopendras, 9 parts, Semen Persicae, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 12
prevent and treat the oral liquid preparation (12) of coronary heart disease remodeling ventricle medicine one
Get 30 parts of Chinese medicine astragalus, 4 parts of Scorpios, 5 parts of Scolopendras, 10 parts, Semen Persicae, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 13
prevent and treat the oral liquid preparation () of coronary heart disease remodeling ventricle medicine two
Get 20 parts of Chinese medicine astragalus, 4 parts of Scorpios, 4 parts of Scolopendras, 15 parts, Semen Persicae, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 14
prevent and treat the oral liquid preparation (two) of coronary heart disease remodeling ventricle medicine two
Get 40 parts of Chinese medicine astragalus, 2 parts of Scorpios, 8 parts of Scolopendras, 9 parts, Semen Persicae, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 15
prevent and treat the oral liquid preparation (three) of coronary heart disease remodeling ventricle medicine two
Get 20 parts of Chinese medicine astragalus, 4 parts of Scorpios, 8 parts of Scolopendras, 15 parts, Semen Persicae, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 16
prevent and treat the oral liquid preparation (four) of coronary heart disease remodeling ventricle medicine two
Get 40 parts of Chinese medicine astragalus, 2 parts of Scorpios, 4 parts of Scolopendras, 9 parts, Semen Persicae, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 17
prevent and treat the oral liquid preparation (five) of coronary heart disease remodeling ventricle medicine two
Get 20 parts of Chinese medicine astragalus, 4 parts of Scorpios, 8 parts of Scolopendras, 15 parts, Semen Persicae, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 18
prevent and treat the oral liquid preparation (six) of coronary heart disease remodeling ventricle medicine two
Get 40 parts of Chinese medicine astragalus, 2 parts of Scorpios, 4 parts of Scolopendras, 15 parts, Semen Persicae, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 19
prevent and treat the oral liquid preparation (seven) of coronary heart disease remodeling ventricle medicine two
Get 30 parts of Chinese medicine astragalus, 3 parts of Scorpios, 6 parts of Scolopendras, 12 parts, Semen Persicae, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 20
prevent and treat the oral liquid preparation (eight) of coronary heart disease remodeling ventricle medicine two
Get 25 parts of Chinese medicine astragalus, 3 parts of Scorpios, 7 parts of Scolopendras, 11 parts, Semen Persicae, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 21
prevent and treat the oral liquid preparation (nine) of coronary heart disease remodeling ventricle medicine two
Get 35 parts of Chinese medicine astragalus, 4 parts of Scorpios, 5 parts of Scolopendras, 13 parts, Semen Persicae, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 22
prevent and treat the oral liquid preparation (ten) of coronary heart disease remodeling ventricle medicine two
Get 25 parts of Chinese medicine astragalus, 2 parts of Scorpios, 7 parts of Scolopendras, 12 parts, Semen Persicae, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 23
prevent and treat the oral liquid preparation (11) of coronary heart disease remodeling ventricle medicine two
Get 40 parts of Chinese medicine astragalus, 2 parts of Scorpios, 6 parts of Scolopendras, 9 parts, Semen Persicae, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 24
prevent and treat the oral liquid preparation (12) of coronary heart disease remodeling ventricle medicine two
Get 30 parts of Chinese medicine astragalus, 4 parts of Scorpios, 5 parts of Scolopendras, 10 parts, Semen Persicae, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 25
prevent and treat the oral liquid preparation () of coronary heart disease remodeling ventricle medicine three
Get 20 parts of Chinese medicine astragalus, 4 parts of Scorpios, 4 parts of Scolopendras, 15 parts, Semen Persicae, 10 parts of Fructus Aurantiis, 70 parts of Radix Salviae Miltiorrhizaes, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 26
prevent and treat the oral liquid preparation (two) of coronary heart disease remodeling ventricle medicine three
Get 40 parts of Chinese medicine astragalus, 2 parts of Scorpios, 8 parts of Scolopendras, 9 parts, Semen Persicae, 20 parts of Fructus Aurantiis, 40 parts of Radix Salviae Miltiorrhizaes, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 27
prevent and treat the oral liquid preparation (three) of coronary heart disease remodeling ventricle medicine three
Get 20 parts of Chinese medicine astragalus, 4 parts of Scorpios, 8 parts of Scolopendras, 15 parts, Semen Persicae, 20 parts of Fructus Aurantiis, 70 parts of Radix Salviae Miltiorrhizaes, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 28
prevent and treat the oral liquid preparation (four) of coronary heart disease remodeling ventricle medicine three
Get 40 parts of Chinese medicine astragalus, 2 parts of Scorpios, 4 parts of Scolopendras, 9 parts, Semen Persicae, 10 parts of Fructus Aurantiis, 70 parts of Radix Salviae Miltiorrhizaes, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 29
prevent and treat the oral liquid preparation (five) of coronary heart disease remodeling ventricle medicine three
Get 20 parts of Chinese medicine astragalus, 4 parts of Scorpios, 8 parts of Scolopendras, 15 parts, Semen Persicae, 10 parts of Fructus Aurantiis, 40 parts of Radix Salviae Miltiorrhizaes, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 30
prevent and treat the oral liquid preparation (six) of coronary heart disease remodeling ventricle medicine three
Get 40 parts of Chinese medicine astragalus, 2 parts of Scorpios, 4 parts of Scolopendras, 15 parts, Semen Persicae, 20 parts of Fructus Aurantiis, 60 parts of Radix Salviae Miltiorrhizaes, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 31
prevent and treat the oral liquid preparation (seven) of coronary heart disease remodeling ventricle medicine three
Get 30 parts of Chinese medicine astragalus, 3 parts of Scorpios, 6 parts of Scolopendras, 12 parts, Semen Persicae, 15 parts of Fructus Aurantiis, 50 parts of Radix Salviae Miltiorrhizaes, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 32
prevent and treat the oral liquid preparation (eight) of coronary heart disease remodeling ventricle medicine three
Get 25 parts of Chinese medicine astragalus, 3 parts of Scorpios, 7 parts of Scolopendras, 11 parts, Semen Persicae, 15 parts of Fructus Aurantiis, 70 parts of Radix Salviae Miltiorrhizaes, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 33
prevent and treat the oral liquid preparation (nine) of coronary heart disease remodeling ventricle medicine three
Get 35 parts of Chinese medicine astragalus, 4 parts of Scorpios, 5 parts of Scolopendras, 13 parts, Semen Persicae, 18 parts of Fructus Aurantiis, 62 parts of Radix Salviae Miltiorrhizaes, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 34
prevent and treat the oral liquid preparation (ten) of coronary heart disease remodeling ventricle medicine three
Get 25 parts of Chinese medicine astragalus, 2 parts of Scorpios, 7 parts of Scolopendras, 12 parts, Semen Persicae, 12 parts of Fructus Aurantiis, 60 parts of Radix Salviae Miltiorrhizaes, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 35
prevent and treat the oral liquid preparation (11) of coronary heart disease remodeling ventricle medicine three
Get 40 parts of Chinese medicine astragalus, 2 parts of Scorpios, 6 parts of Scolopendras, 9 parts, Semen Persicae, 12 parts of Fructus Aurantiis, 40 parts of Radix Salviae Miltiorrhizaes, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 36
prevent and treat the oral liquid preparation (12) of coronary heart disease remodeling ventricle medicine three
Get 30 parts of Chinese medicine astragalus, 4 parts of Scorpios, 5 parts of Scolopendras, 10 parts, Semen Persicae, 18 parts of Fructus Aurantiis, 62 parts of Radix Salviae Miltiorrhizaes, put and decoct in container, add the water soaking 1h of 5 times of amounts, boil 30 min, filter.Medicinal residues add the water of 4 times of amounts to continue to decoct, and boil 20 min, filter.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, the cooling sterilizing medicine bottle that packs into, puts 4 ℃ of refrigerators standby.
embodiment 37
prevent and treat the preparation of coronary heart disease remodeling ventricle medicinal tablet/capsule
Get the arbitrary described medicine of embodiment 1-36, add 5-8 times of water gaging, decoct 4 hours, leach medicine juice.Add again 6-10 times of water gaging, decoct 2-3 hour, leach medicine juice, merge secondary decocting liquid, standing, leaching supernatant, concentrated, let cool, add 3 times of amount ethanol of concentrated solution, stir precipitation and spend the night.Get supernatant, be concentrated into thick extractum; Add pharmaceutical aids, vacuum drying, pulverizes and granulates, and is pressed into tablet or fills encapsulated.
embodiment 38
prevent and treat the preparation of coronary heart disease remodeling ventricle drug particles
Get the arbitrary described medicine of embodiment 1-36, add 8 times of water gagings, decoct 3 hours, leach medicine juice.Add again 8 times of water gagings, decoct 1 hour, leach medicine juice, merge secondary decocting liquid, standing, leaching supernatant, concentrated, let cool, add 2 times of amount ethanol of concentrated solution, stir precipitation and spend the night.Get supernatant, be concentrated into thick extractum; Add suitable pharmaceutical aids, granulate, dry, granulate, obtains 20g granule, subpackage 10g/ bag.
embodiment 39
prevent and treat the preparation of coronary heart disease remodeling ventricle drug mixture/syrup
Get the arbitrary described medicine of embodiment 1-36, add 12 times of water gagings, decoct 3-4 hour, leach medicine juice.Add again 8 times of water gagings, decoct 3 hours, leach medicine juice, merge secondary decocting liquid, standing, leaching supernatant, concentrated, let cool, add 3 times of amount ethanol of concentrated solution, stir precipitation and spend the night.Get supernatant, be concentrated into thick extractum; Add suitable pharmaceutical aids, make mixture or syrup.
embodiment 40
the intervention test of Chinese medicine composition of the present invention to Left Ventricular Remodeling after Acute Myocardial Infarction
1 data and method
1.1 case selections and grouping
All cases derives from the patient that in JIUYUE, 2000 to 2002 is in hospital at the hospital of traditional Chinese hospital, Shanghai Cardiological year October.Wherein male's 42 examples, women's 38 examples, age 35-78 year, average 67 ± 5 years old.According to inclusion criteria, be divided at random treatment group 1, treatment group 2, treatment group 3 and Monopril (contrast) group, each 20 examples, four groups of patients' age, sex there was no significant difference (P>0.05).
1.2 Therapeutic Method
Treatment group 1, treatment group 2, treatment group 3 start to give the medicine oral liquid for the treatment of remodeling ventricle prepared by embodiment 7, embodiment 19, embodiment 31 being admitted to hospital in 24h, every day potion, potion 150ml, oral at twice.
Monopril (contrast) group gives Monopril (fosinopril is purchased from Huahai Pharmaceutical Co., Ltd., Zhejiang), starts 5mg, once a day, and oral maintaining; As normal in blood pressure, increase to 10mg, once a day, maintain one week; As systolic pressure >=100mmHg, and have no adverse reaction, dosage can be increased to 20mg gradually, once a day.All accept conventional medicine for five groups and comprise the treatments such as beta-blocker, diuretic, nitrate esters, anticoagulant, fat regulation medicine, arrhythmia.Be 6 months the course for the treatment of.
1.3 observation index
Adopt hewlette-packard HP5500 type sonos two-dimensional ultrasound cardiograph, frequency probe 3.5mHz.Respectively at (7-14d after being admitted to hospital) before leaving hospital, within after AMI 3 months and 6 months, detect LVEDVI, LVESVI, LvmssI, EF, E/A, WMI, WT.Detect AT II in blood plasma, ALD, ET level simultaneously.
2 statistical procedures
Data are all used the processing of SPSS 11.0 statistical softwares.Data represent with ± S, adopt t check to carry out statistical analysis.
3 results
3.1 4 groups of patient's echocardiographic parameters comparative results are in Table 1.
Four groups of patient's echocardiographic parameters of table 1 change (X meansigma methods ± S)
Note: with leave hospital before relatively: ↑ P<0.05, ↑ ↑ P <0.01.
As can be seen from Table 1, LVEDVI and LVESVI: four groups before leaving hospital bulk of left ventricle all in normal range, at 3 months, 6 months its volumes all without obviously increasing, there was no significant differences (P>0.05) relatively in four groups; EF and E/A: four groups of EF and E/A increase gradually with the prolongation for the treatment of time, four groups 6 months with leave hospital before significance (P<0.05 and P<0.01) relatively; LvmassI and WT: result shows and alleviate gradually along with the prolongation for the treatment of time, four groups 6 months with leave hospital before the equal significance (P<0.05) of comparing; Four groups leave hospital before WMI all have obviously extremely, after treatment, WMI presents the trend of recovering gradually, but 3 months, 6 months with leave hospital before not statistically significant (P>0.05) relatively.More equal no difference of science of statistics (P>0.05) between four groups of These parameters.
3.2 4 groups of patient's blood plasma ET, AT II, ALD comparative result are in Table 2.
The variation (± S) of four groups of patient ET of table 2, AT II, ALD
| Group | ? | ET(ng/ml) | ATⅡ(pg/ml) | ALD(pg/ml) |
| Treatment group 1(20) | Before leaving hospital | 72.60±15.67 | 75.05±15.77 | 124.70±25.26 |
| ? | 3 months | 65.80±11.88★ | 73.08±14.49 | 123.20±24.61 |
| ? | 6 months | 57.90±11.55★★▲ | 70.30±15.23 | 117.40±24.68 |
| Treatment group 2(20) | Before leaving hospital | 73.79±14.90 | 73.49±13.49 | 126.08±25.04 |
| ? | 3 months | 66.93±10.76★ | 75.03±15.43 | 124.01±25.47 |
| ? | 6 months | 56.27±10.25★★▲ | 72.42±16.10 | 119.51±24.75 |
| Treatment group 3(20) | Before leaving hospital | 74.19±14.82 | 74.98±16.04 | 123.92±24.29 |
| ? | 3 months | 64.76±12..72★ | 74.50±13.16 | 125.83±25.42 |
| ? | 6 months | 56.19±12.04★★▲ | 71.42±12.00 | 116.17±22.46 |
| Monopril group (20) | Before leaving hospital | 74.33±14.44 | 71.08±15.20 | 111.40±19.78 |
| ? | 3 months | 73.35±11.62 | 63.90±13.86﹡ | 104.75±18.39﹡ |
| ? | 6 months | 71.05±11.33 | 59.95±10.26﹡? ?△ | 96.75±17.57﹡﹡? △ |
Note: with the comparison of Monopril group: ★ P<0.05, ★ ★ P<0.01; With leave hospital before relatively: ▲ P<0.01.With treatment group comparison: * P<0.05, * * P<0.01; With leave hospital before relatively: △ P<0.05.
As can be seen from Table 2, four groups of ET, AT II, ALD all have rising before leaving hospital.After treatment, treatment group 1-3 is compared with the ET of Monopril group (3 months P<0.05 that obviously decline; 6 months P<0.01), treatment group 1-3 treatment 6 months with leave hospital before more all have remarkable statistical significance (P<0.01).And Monopril group and treatment group 1-3 relatively can obviously reduce plasma A T II, ALD level (3 months, 6 months P<0.05 or P<0.01), Monopril group 6 months with leave hospital before more also significance (P<0.05).
GCP principle is strictly followed in this research, according to completely random, contrast, single blind design method, studies.Observe under study for action the indexs such as routine blood test, routine urinalysis, hepatic and renal function, result does not have serious adverse reaction to occur, and has two people to occur gastrointestinal reaction, after listening medicine, disappears, and has proved the safety of Chinese medicine simultaneously.
This clinical research result confirms that three kinds of Chinese medicine compositions all can improve wall motion index, and cardiac ejection fraction, alleviates locular wall plumpness and ventricular mass, suppress the expansion of ventricular chamber, reduce the concentration of endothelin level simultaneously, obtain good clinical efficacy, its curative effect and Western medicine Monopril are basically identical.But Western medicine has certain toxic and side effects, and medicine of the present invention has no side effect, high safety.
In medicine, the Radix Astragali is monarch's replenishing qi and promoting blood flow; Ministerial drug Scorpio, Scolopendra activating blood circulation to dissipate blood stasis dredging collateral; Assistant is with Semen Persicae blood circulation promoting and blood stasis dispelling, Fructus Aurantii vital energy regualting and blood circulation-promoting, Radix Salviae Miltiorrhizae blood circulation promoting and blood stasis dispelling, tranquilizing by nourishing the heart.All medicines share the effect of playing altogether benefiting QI for activating blood circulation, regulating qi and dredging collateral, tranquilizing by nourishing the heart.Modern pharmacological research confirms: these Chinese medicines have coronary artery dilating, antiplatelet aggregation, and antithrombotic forms, and reduces blood viscosity, improves microcirculation; The Radix Astragali, Radix Salviae Miltiorrhizae have more and improve circulation endothelium progenitor cell function, angiogenesis promoting and endothelium repair function.
It is also not clear that medicine of the present invention improves after heart infarction the final mechanism of remodeling ventricle.But its possible mechanism is: 1) Chinese medicine is formed, reduces blood viscosity, improved microcirculation by coronary artery dilator, antiplatelet aggregation, antithrombotic, thereby promotes the increase of side shoot blood flow, and local hibernating myocardium presses down cardiac muscle recovery with pausing.2) Chinese medicine, by the adjusting to endothelium, reduces the synthetic of ET and discharges, and prevents interstitial fibrosis, thereby alleviates left ventricular remodeling.3) extract of the Radix Astragali has cardiotonic, and energy blood vessel dilating, reduces blood pressure.Chinese medicine, by improving hemodynamics, reduces myocardial oxygen consumption, cardiac output is increased, thereby improve heart contraction and diastolic function.
embodiment 41
the Curative effect of Chinese medicine composition of the present invention to coronary heart disease triple vessel disease remodeling ventricle and cardiovascular event
1 data and method:
1.1 clinical datas: during MethodsThe cases enrolled all derives from July, 2008～2009 year August, Shanghai Chinese Medicine Hospital institute Cardiological is in hospital and out-patient.Follow random contrast principle, adopt table of random number method to be divided into: treat one group, treat two groups, treatment three groups and each 30 examples of matched group.Have 1 routine patient disallowable because receive by mistake (treating three groups), 4 routine patients can not coordinate and follow up a case by regular visits to and complete index of correlation check and come off (treat one group of 1 example, treat three group of 1 example, matched group 2 examples), and totally 115 routine patients have completed this clinical trial.Three groups of patients' age, sex, height, body weight, body surface area (body surface area, BSA), clinical medical history, blood pressure, Primary Care medication refers to table 3, difference (P>0.05) that significance analysis result shows between each group that there are no significant.
Four groups of patient's basic conditions of table 3
The diagnostic criteria of 1.2 coronary heart disease
According to the suggestion of first national internal medicine academic conference in 1980, with reference to " name of ischemic heart desease and the diagnostic criteria " of World Health Organization's formulation in 1979.
1.3 inclusive criterias and exclusion standard
Inclusive criteria: 1. the equal underwent coronary radiography of patient is made a definite diagnosis three pathological changes of coronary heart disease, through Cardiological, Cardiac Surgery diagnosis had both been not suitable for percutaneous transluminal coronary stent implantation, was not suitable for again the patient of coronary artery bypass; Or underwent coronary radiography makes a definite diagnosis three pathological changes of coronary heart disease, patient and family members abandon the patient of row percutaneous transluminal coronary stent implantation and coronary artery bypass; 2. age 55-75 year, male or female; 3. be ready to give one's cooperation and the person that do not meet exclusion standard.Exclusion standard: 1. 4 grades of cardiac function or pulmonary edema person; 2. serious hepatic and kidney function obstacle person; 3. Chinese medicine allergy sufferers; 4. the malignant disease person of having occurred together; 5. serious inflammatory diseases person; 6. there is hemorrhage person; 7. be reluctant partner.
1.4 method
Adopt the Clinical design (doctor who only clinical indices is detected carries out blind method design) of completely random, contrast, blind method.Four groups all with anti-platelet agent, nitrate esters, beta-Blocking agent, ACEI(or ARB), calcium ion blocker, statinses etc. are as Primary Care.Treat three groups of one group, two groups of treatments and treatments and in Primary Care, add respectively medicine prepared by embodiment 7, embodiment 19 and embodiment 31, every day three times, a 100ml; Matched group only adopts Primary Care; In the total June course for the treatment of, after finishing the course for the treatment of, continue to follow up a case by regular visits to 6 months.
1.5 cardiac ultrasonic indexs
Adopt hewlette-packard HP5500 type two-dimensional ultrasound cardiograph, frequency probe 3.5mHz.Respectively at observing remodeling ventricle index with treatment after 6 months before treatment, comprise left ventricular end-diastolic volume index (left ventricular end-diastolic volume index, LVEDVI), left ventricular end-systolic volume index (left ventricular end-systolic volume index, LVESVI), Left ventricular mass index (left ventricular mass index, LVMI), ejection fraction (ejection fraction, EF), E peak/A p-ratio (E/A ratio), wall motion index (wall motion index, WMI), chamber wall thickness (wall thickness, WT).These parameters according to the evaluation criteria of seminar regulation by special messenger's operation detection, respectively at left chamber major axis, minor axis, apex two chamber figure, observe on four chamber figure, to obtain maximum left chamber major axis major diameter and endocardium area.By electrocardiogram, determine systole and relaxing period, with photostyle system structure, go out left chamber area, and obtained a result by computer system.LVMI is by according to Devereux formula (Devereux RB, Alonso DR, Lutas EM, et al: Echocardiographic assessment of left ventricular hypertrophy:comparison to necropsy findings. AM J Cardial, 1986.57 (6): 450-8.) calculate.
1.6 cardiovascular event definition
Cardiovascular event is defined as cardiovascular death event and non-death incident, death incident comprises cardiac death, sudden death and all unknown cause death, and non-death incident comprises heart failure, myocardial infarction, unstable angina pectoris, severe arrhythmia and apoplexy.
1.7 safety indexes
In observation, follow up a case by regular visits to after one week and 4th week detection routine blood test, urine routine, stool routine examination, blood pressure, hepatic and renal function, electrolyte, blood glucose, electrocardiogram etc.
1.8 statistical procedures
Application SPSS 17.0 statistical softwares carry out data analysis.Measurement data data with mean (
) ± standard deviation (s) represents, relatively adopts independent t check between group; Before and after group internal therapy, relatively adopt paired t-test; Enumeration data adopts χ
2check.
2 results
2.1 cardiac ultrasonic indexs:
1. four groups of patients' LVESVI, EF between comparison and group, relatively there are no significant before and after treatment difference (P>0.05).2. treat after one group, the WT treatment of two groups of treatments, three groups of treatments on a declining curve, but with treatment before there was no significant difference relatively, and matched group has no this trend, there was no significant difference (P>0.05) relatively before and after treatment and between group.3. treat before and after one group, the E/A ratio treatment of two groups of treatments, three groups of treatments relatively there was no significant difference (P>0.05), the E/A ratio for the treatment of of control group after 6 months decreases before treating, and has significant difference (P<0.01); Between group relatively show, the treatment E/A ratio of latter 6 months of matched group treat one group, treatment two groups, treatment three groups obviously reduce, have significant difference (P<0.05); 4. treat one group, the LVEDVI of two groups of treatments, three groups of treatments and make moderate progress after 6 months in treatment, and relatively have significant difference (P<0.05) before treatment; Before and after matched group LVEDVI treatment, compare there was no significant difference (P>0.05); Between group, compare there was no significant difference (P>0.05); 5. treat one group, treatment two groups, treatment three groups treatment June after LVMI decline, with treatment before relatively have significant difference (P<0.01); After treatment of control group June, LVMI raises, and relatively has significant difference (P<0.01) before treatment; Between group, more also there is significant difference (P<0.01); 6. treat one group, treatment two groups, treatment three groups treatment June after WMI decline, with treatment before relatively have significant difference (P<0.001); After treatment of control group June, WMI raises, and relatively has significant difference (P<0.01) before treatment; Between group, compare there was no significant difference (P>0.05), refer to table 4.
Four groups of patients' of table 4 cardiac ultrasonic index change (
, n=28)
* with matched group comparison, P<0.05; * and matched group comparison, P<0.01; # is relatively front with treatment, P<0.01; ## is relatively front with treatment, P<0.001; ### is relatively front with treatment, P<0.05; #### is relatively front with treatment.
2.2 cardiovascular events are followed up a case by regular visits to
Follow up a case by regular visits to altogether 12 months, treat one group of generation cardiovascular times 4 example, wherein unstable angina 3 examples, heart failure be again in hospital 1 example; Treat two groups of generation cardiovascular times 4 examples, wherein unstable angina 3 examples, heart failure be again in hospital 1 example; Treat three groups of generation cardiovascular event 6 examples, wherein unstable angina 5 examples, heart failure be again in hospital 1 example; Matched group generation cardiovascular event 8 examples, wherein unstable angina 6 examples, heart failure be again in hospital 1 example, apoplexy (cerebral infarction) 1 example; Four groups are compared there was no significant difference (P>0.05).
2.3 safety indexes
Four groups of safety indexes show no obvious abnormalities.
2.4 untoward reaction
Treating three groups has 2 examples to have slight gastrointestinal reaction (comprise nauseating, epigastrium distension), and matched group has 1 example to occur similar reaction.Lighter because of untoward reaction, after explaining patiently, after patient continues medication, gastrointestinal reaction alleviates or disappears.
This embodiment result shows, Drug therapy coronary heart disease triple vessel disease of the present invention is after 6 months, and Left ventricular mass index, wall motion index and left ventricular end diastolic volume index decreased and more all have significant difference before treatment; Chamber wall thickness is also on a declining curve, but with treatment before there was no significant difference relatively; And treatment of control group after 6 months Left ventricular mass index raise, wall motion index raises, and relatively has significant difference before treatment, shows that medicine of the present invention can improve remodeling ventricle, can improve the local motion of ventricle wall simultaneously.The E/A ratio for the treatment of of control group after 6 months decreases before treating in addition, and relatively show between group, the treatment E/A ratio of latter 6 months of matched group obviously reduces compared with treatment group, all there is significant difference, show that matched group left ventricular diastolic function has the trend going down, and use Drug therapy of the present invention can improve the diastolic function of left chamber.In a word, Chinese medicine composition of the present invention can improve the diastolic function of left chamber, improves remodeling ventricle, improves the local motion of ventricle wall, plays the effect that promoting blood circulation to remove obstruction in the collateral, QI invigorating activate yang, giving consideration to both the incidental and fundamental.
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, do not departing under the prerequisite of the inventive method; can also make some improvement and supplement, these improvement and the supplementary protection scope of the present invention that also should be considered as.
Claims (5)
1. a Chinese medicine composition of preventing and treating coronary heart disease remodeling ventricle, is characterized in that, it is to be made by the crude drug of following weight portion: Radix Astragali 20-40 part, Scorpio 2-4 part, Scolopendra 4-8 part, Semen Persicae 9-15 part.
2. Chinese medicine composition according to claim 1, is characterized in that, the weight portion of described Semen Persicae is 12 parts.
3. a Chinese medicine composition of preventing and treating coronary heart disease remodeling ventricle, is characterized in that, it is to be made by the crude drug of following weight portion: Radix Astragali 20-40 part, Scorpio 2-4 part, Scolopendra 4-8 part, Semen Persicae 9-15 part, Fructus Aurantii 10-20 part, Radix Salviae Miltiorrhizae 40-70 part.
4. Chinese medicine composition according to claim 3, is characterized in that, the weight portion of described Fructus Aurantii is 15 parts, and the weight portion of described Radix Salviae Miltiorrhizae is 50 parts.
5. according to the arbitrary described Chinese medicine composition of claim 1-4, it is characterized in that, the medicament of described Chinese medicine composition is capsule, granule, tablet, oral liquid, mixture or syrup.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110407138.XA CN102416036B (en) | 2011-12-09 | 2011-12-09 | Traditional Chinese medicinal compositions for preventing and treating ventricular reconstruction due to coronary heart disease and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110407138.XA CN102416036B (en) | 2011-12-09 | 2011-12-09 | Traditional Chinese medicinal compositions for preventing and treating ventricular reconstruction due to coronary heart disease and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102416036A CN102416036A (en) | 2012-04-18 |
| CN102416036B true CN102416036B (en) | 2014-05-07 |
Family
ID=45940838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110407138.XA Expired - Fee Related CN102416036B (en) | 2011-12-09 | 2011-12-09 | Traditional Chinese medicinal compositions for preventing and treating ventricular reconstruction due to coronary heart disease and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102416036B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105853847A (en) * | 2016-05-25 | 2016-08-17 | 上海市中医医院 | Traditional Chinese medicine composition for treating triple-vessel disease of coronary heart disease and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101322801A (en) * | 2007-06-15 | 2008-12-17 | 河北以岭医药研究院有限公司 | Use of Chinese medicinal composition in preparing medicament for treating dilated cardiomyopathy |
| CN101590180A (en) * | 2008-05-30 | 2009-12-02 | 河北以岭医药研究院有限公司 | The application of a kind of Chinese medicine composition in preparation inhibition apoptosis of cardiac muscle medicine |
| CN101991638A (en) * | 2010-11-26 | 2011-03-30 | 潘畅 | Medicine composition for treating facial paralysis as well as preparation method and application thereof |
| CN102048900A (en) * | 2009-11-09 | 2011-05-11 | 景松森 | Traditional Chinese medicine preparation for treating lumbar intervertebral disc protrusion |
-
2011
- 2011-12-09 CN CN201110407138.XA patent/CN102416036B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101322801A (en) * | 2007-06-15 | 2008-12-17 | 河北以岭医药研究院有限公司 | Use of Chinese medicinal composition in preparing medicament for treating dilated cardiomyopathy |
| CN101590180A (en) * | 2008-05-30 | 2009-12-02 | 河北以岭医药研究院有限公司 | The application of a kind of Chinese medicine composition in preparation inhibition apoptosis of cardiac muscle medicine |
| CN102048900A (en) * | 2009-11-09 | 2011-05-11 | 景松森 | Traditional Chinese medicine preparation for treating lumbar intervertebral disc protrusion |
| CN101991638A (en) * | 2010-11-26 | 2011-03-30 | 潘畅 | Medicine composition for treating facial paralysis as well as preparation method and application thereof |
Non-Patent Citations (6)
| Title |
|---|
| 双龙丸抗动脉粥样硬化及血管内皮保护作用的临床研究;张健元等;《上海中医药杂志》;20010715(第7期);全文 * |
| 张健元等.双龙丸抗动脉粥样硬化及血管内皮保护作用的临床研究.《上海中医药杂志》.2001,(第7期), |
| 通心方对冠心病三支血管病变心室重构及心血管事件的影响;邢健东等;《中国中医急症》;20101031;第19卷(第10期);全文 * |
| 通心方对冠心病三支血管病变心室重构的影响;邢健东等;《陕西中医》;20100605;第31卷(第6期);第643页 * |
| 邢健东等.通心方对冠心病三支血管病变心室重构及心血管事件的影响.《中国中医急症》.2010,第19卷(第10期), |
| 邢健东等.通心方对冠心病三支血管病变心室重构的影响.《陕西中医》.2010,第31卷(第6期),第643-645页. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102416036A (en) | 2012-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102078510B (en) | Chinese medicinal composition for treating coronary heart disease | |
| CN103816280B (en) | Traditional Chinese medicine composition for treating myocardial infarction and application of traditional Chinese medicine composition | |
| CN101088546A (en) | Heart-benefiting Yixinshu micropill and its prepn process | |
| CN104013919A (en) | Traditional Chinese medicine for treating angina pectoris | |
| CN102416036B (en) | Traditional Chinese medicinal compositions for preventing and treating ventricular reconstruction due to coronary heart disease and use thereof | |
| CN102526631B (en) | Traditional Chinese medicine preparation, tablet and capsule for curing dilated cardiomyopathy and preparation method | |
| CN104147346A (en) | Traditional Chinese medicinal compound for treating coronary diffuse lesion angina | |
| CN101342207B (en) | Chinese medicinal composition for treating coronary disease, stenocardia, arrhythmia, hyperlipemia and preparation method thereof | |
| CN103610936A (en) | Chinese medicinal preparation for treating coronary heart disease and preparation method thereof | |
| CN102988747B (en) | Aristida triseta electuary for reducing hypertension, hyperglycemia and hyperlipidemia and preparation method thereof | |
| CN102579804B (en) | Chinese medicine for treating stenocardia | |
| CN102309561B (en) | Pharmaceutical composition used for preventing and treating urarthritis and hyperuricemia | |
| CN105126034A (en) | Pharmaceutical preparation for treating coronary heart disease | |
| CN106620253B (en) | Traditional Chinese medicine composition for treating bradyarrhythmia | |
| CN114796420B (en) | Traditional Chinese medicine composition for treating non-valvular atrial fibrillation as well as traditional Chinese medicine preparation and application thereof | |
| CN102861231A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating ventricular remodeling after myocardial infarction | |
| CN104189288B (en) | A kind of Chinese medicine composition for treating myocardial infarction and its application | |
| CN103893694B (en) | A kind of medicine for treating coronary heart disease | |
| CN101229314B (en) | Chinese traditional medicine preparation for treating myocardial infarction induced by myocardial ischemia | |
| CN107456481A (en) | A kind of Chinese medicine composition for treating coronary disease and angina pectoris and preparation method thereof | |
| CN102008539A (en) | Medicinal composition for treating diseases such as vital myocarditis and dilated cardiomyopathy and preparation process thereof | |
| CN102274514B (en) | Medicinal composition for preventing and treating type-II diabetes and complications thereof | |
| CN105168653A (en) | Traditional Chinese medicine composition used for treating coronary heart disease | |
| CN104524313A (en) | Traditional Chinese medicine preparation for treating sick sinus syndrome | |
| CN104208571A (en) | Traditional Chinese medicinal composition for treating cardiovascular stenosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140507 Termination date: 20151209 |
|
| EXPY | Termination of patent right or utility model |